Skip to main content

Articles

Page 3 of 63

  1. Chimeric Antigen Receptor (CAR) T cells are now standard of care (SOC) for some patients with B cell and plasma cell malignancies and could disrupt the therapeutic landscape of solid tumors. However, access to...

    Authors: Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, Andrew G. Mancini, Gavin L. Kurgan, Carley Fowler, Peng Xu, Xikun Liu, Kyle Asano, Sunny Patel, Christopher J. Fisher, Annie K. Brown, Ramya H. Tunuguntla, Shabnum Patel, Elena Sotillo, Crystal L. Mackall…
    Citation: Molecular Cancer 2023 22:100
  2. Lung adenocarcinoma (LUAD) is a common type of lung cancer with a high risk of metastasis, but the exact molecular mechanisms of metastasis are not yet understood.

    Authors: Han Fang, Qi Sun, Jin Zhou, Huijuan Zhang, Qiong Song, Hua Zhang, Guohua Yu, Ying Guo, Chengyu Huang, Yakui Mou, Chuanliang Jia, Yingjian Song, Aina Liu, Kaiyu Song, Congxian Lu, Ruxian Tian…
    Citation: Molecular Cancer 2023 22:99
  3. Cancer is a grievous disease whose treatment requires a more efficient, non-invasive therapy, associated with minimal side effects. Gold nanoparticles possessing greatly impressive optical properties have been...

    Authors: Prashant Kesharwani, Ruiyang Ma, Liang Sang, Mahak Fatima, Afsana Sheikh, Mohammed A. S. Abourehab, Neelima Gupta, Zhe-Sheng Chen and Yun Zhou
    Citation: Molecular Cancer 2023 22:98
  4. Authors: Rodrigo Entrialgo‑Cadierno, Cristina Cueto‑Ureña, Connor Welch, Iker Feliu, Irati Macaya, Laura Vera, Xabier Morales, Sandra Vietti Michelina, Pietro Scaparone, Ines Lopez, Elodie Darbo, Oihane Erice, Adrian Vallejo, Haritz Moreno, Ainhoa Goñi‑Salaverri, David Lara‑Astiaso…
    Citation: Molecular Cancer 2023 22:97

    The original article was published in Molecular Cancer 2023 22:86

  5. Cancer is the most prevalent cause of death globally, and radiotherapy is considered the standard of care for most solid tumors, including lung, breast, esophageal, and colorectal cancers and glioblastoma. Res...

    Authors: Yu Wu, Yingqiu Song, Runze Wang and Tianlu Wang
    Citation: Molecular Cancer 2023 22:96
  6. Clinical hyperthermic intraperitoneal chemotherapy (HIPEC) is regarded as a potential treatment that can prolong survival of patients with peritoneal metastases after cytoreductive surgery. However, treated tu...

    Authors: Qiang Wang, Peng Liu, Yingfei Wen, Kuan Li, Bo Bi, Bin-bin Li, Miaojuan Qiu, Shiqiang Zhang, You Li, Jia Li, Hengxing Chen, Yuan Yin, Leli Zeng, Changhua Zhang, Yulong He and Jing Zhao
    Citation: Molecular Cancer 2023 22:95
  7. Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary cancer treatment modality, offering long-lasting responses and survival benefits for a substantial number of cancer pat...

    Authors: Xianjing Chu, Wentao Tian, Ziqi Wang, Jing Zhang and Rongrong Zhou
    Citation: Molecular Cancer 2023 22:93

    The Correction to this article has been published in Molecular Cancer 2023 22:101

  8. Though the CXCR2 chemokine receptor is known to play a key role in cancer growth and response to therapy, a direct link between expression of CXCR2 in tumor progenitor cells during induction of tumorigenesis h...

    Authors: J. Yang, K. Bergdorf, C. Yan, W. Luo, S. C. Chen, G.D. Ayers, Q. Liu, X. Liu, M. Boothby, V.L. Weiss, S. M. Groves, A. N. Oleskie, X. Zhang, D. Y. Maeda, J. A. Zebala, V. Quaranta…
    Citation: Molecular Cancer 2023 22:92
  9. Cancer therapy resistance is the main cause of cancer treatment failure. The mechanism of therapy resistance is a hot topic in epigenetics. As one of the most common RNA modifications, N6-methyladenosine (m6A)...

    Authors: Hengzhao Zhuang, Bo Yu, Dan Tao, Xiaoyan Xu, Yijun Xu, Jian Wang, Yang Jiao and Lili Wang
    Citation: Molecular Cancer 2023 22:91
  10. Epithelial mesenchymal transition (EMT) and mesenchymal epithelial transition (MET) are genetic determinants of cellular plasticity. These programs operate in physiological (embryonic development, wound healin...

    Authors: Azamat Akhmetkaliyev, Noura Alibrahim, Darya Shafiee and Eugene Tulchinsky
    Citation: Molecular Cancer 2023 22:90
  11. Chemoresistance is a major cause of treatment failure in colorectal cancer (CRC) therapy. In this study, the impact of the IGF2BP family of RNA-binding proteins on CRC chemoresistance was investigated using in...

    Authors: Sandra Kendzia, Susanne Franke, Tarek Kröhler, Nicole Golob-Schwarzl, Caroline Schweiger, Anna M. Toeglhofer, Christina Skofler, Stefan Uranitsch, Amin El-Heliebi, Julia Fuchs, Andreas Punschart, Philipp Stiegler, Marlen Keil, Jens Hoffmann, David Henderson, Hans Lehrach…
    Citation: Molecular Cancer 2023 22:89
  12. Neuroblastoma is the most common solid tumor in infants accounting for approximately 15% of all cancer-related deaths. Over 50% of high-risk neuroblastoma relapse, emphasizing the need of novel drug targets an...

    Authors: Sven Hagemann, Danny Misiak, Jessica L. Bell, Tommy Fuchs, Marcell I. Lederer, Nadine Bley, Monika Hämmerle, Ehab Ghazy, Wolfgang Sippl, Johannes H. Schulte and Stefan Hüttelmaier
    Citation: Molecular Cancer 2023 22:88
  13. The advent of nanotechnology has opened new possibilities for bioimaging. Metal nanoparticles (such as gold, silver, iron, copper, etc.) hold tremendous potential and offer enormous opportunities for imaging a...

    Authors: Wei Qin, Jyoti Chandra, Mohammed A.S. Abourehab, Neelima Gupta, Zhe-Sheng Chen, Prashant Kesharwani and Hui-Ling Cao
    Citation: Molecular Cancer 2023 22:87
  14. The discovery of functionally relevant KRAS effectors in lung and pancreatic ductal adenocarcinoma (LUAD and PDAC) may yield novel molecular targets or mechanisms amenable to inhibition strategies. Phospholipi...

    Authors: Rodrigo Entrialgo-Cadierno, Cristina Cueto-Ureña, Connor Welch, Iker Feliu, Irati Macaya, Laura Vera, Xabier Morales, Sandra Vietti Michelina, Pietro Scaparone, Ines Lopez, Elodie Darbo, Oihane Erice, Adrian Vallejo, Haritz Moreno, Ainhoa Goñi-Salaverri, David Lara-Astiaso…
    Citation: Molecular Cancer 2023 22:86

    The Correction to this article has been published in Molecular Cancer 2023 22:97

  15. Enhancer of zeste homolog 2 (EZH2), the key catalytic subunit of polycomb repressive complex 2 (PRC2), is overexpressed and plays an oncogenic role in various cancers through catalysis-dependent or catalysis-i...

    Authors: Jianfeng Chen, Jing Han Hong, Yulin Huang, Shini Liu, Jiaxin Yin, Peng Deng, Yichen Sun, Zhaoliang Yu, Xian Zeng, Rong Xiao, Jason Yongsheng Chan, Peiyong Guan, Yali Wang, Peili Wang, Lizhen Liu, Shijun Wen…
    Citation: Molecular Cancer 2023 22:85
  16. Checkpoint blockade immunotherapy, represented by PD-1 or PD-L1 antibody treatment, has been of tremendous success in clinical practice. However, the low clinical response rate and lack of biomarkers for predi...

    Authors: Zongzhi Liu, Xiang Li, Yibo Gao, Jiejie Liu, Yating Feng, Yang Liu, Junyun Wang, Chunmeng Wang, Dongrui Wang, Jie He, Weidong Han, Qian Mei and Yingli Sun
    Citation: Molecular Cancer 2023 22:84
  17. RNA modifications are important regulators of transcript activity and an increasingly emerging body of data suggests that the epitranscriptome and its associated enzymes are altered in human tumors.

    Authors: Vanessa Ortiz-Barahona, Marta Soler, Veronica Davalos, Carlos A. García-Prieto, Maxime Janin, Fernando Setien, Irene Fernández-Rebollo, Joan J. Bech-Serra, Carolina De La Torre, Sonia Guil, Alberto Villanueva, Pei-Hong Zhang, Li Yang, Marco Guarnacci, Ulrike Schumann, Thomas Preiss…
    Citation: Molecular Cancer 2023 22:83
  18. CAR T cell-based therapies have revolutionized the treatment of hematological malignancies such as leukemia and lymphoma within the last years. In contrast to the success in hematological cancers, the treatmen...

    Authors: Lusine Hovhannisyan, Carsten Riether, Daniel M. Aebersold, Michaela Medová and Yitzhak Zimmer
    Citation: Molecular Cancer 2023 22:82
  19. RNA 5-methylcytosine (m5C) modification plays critical roles in the pathogenesis of various tumors. However, the function and molecular mechanism of RNA m5C modification in tumor drug resistance remain unclear.

    Authors: Yueqin Wang, Jingyao Wei, Luyao Feng, Ouwen Li, Lan Huang, Shaoxuan Zhou, Yingjie Xu, Ke An, Yu Zhang, Ruiying Chen, Lulu He, Qiming Wang, Han Wang, Yue Du, Ruijuan Liu, Chunmin Huang…
    Citation: Molecular Cancer 2023 22:81
  20. Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing ...

    Authors: Shengkang Huang, Xinyu Wang, Yu Wang, Yajing Wang, Chenglong Fang, Yazhuo Wang, Sifei Chen, Runkai Chen, Tao Lei, Yuchen Zhang, Xinjie Xu and Yuhua Li
    Citation: Molecular Cancer 2023 22:80
  21. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-018-0844-7.

    Authors: Haihai Liang, Xiaoguang Zhao, Chengyu Wang, Jian Sun, Yingzhun Chen, Guoyuan Wang, Lei Fang, Rui Yang, Mengxue Yu, Yunyan Gu and Hongli Shan
    Citation: Molecular Cancer 2023 22:78
  22. The development of cancer immunotherapeutic strategies relies on the identification and validation of optimal target tumor antigens, which should be tumor-specific as well as able to elicit a swift and potent ...

    Authors: Maria Tagliamonte, Beatrice Cavalluzzo, Angela Mauriello, Concetta Ragone, Franco M. Buonaguro, Maria Lina Tornesello and Luigi Buonaguro
    Citation: Molecular Cancer 2023 22:75
  23. Hypoxia is a hallmark of solid tumors and leads to the metabolic reprogramming of cancer cells. The role of epigenetic regulation between hypoxia and aberrant cholesterol metabolism in colorectal cancer (CRC) ...

    Authors: Li Xiong, Hua-shan Liu, Chi Zhou, Xin Yang, Liang Huang, Hai-qing Jie, Zi-wei Zeng, Xiao-bin Zheng, Wen-xin Li, Zhan-zhen Liu, Liang Kang and Zhen-xing Liang
    Citation: Molecular Cancer 2023 22:72
  24. Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curati...

    Authors: Bo Li, Hui Chen, Shaohua Yang, Feng Chen, Liangliang Xu, Yan Li, Mingzhe Li, Chengming Zhu, Fangyuan Shao, Xinhua Zhang, Chuxia Deng, Leli Zeng, Yulong He and Changhua Zhang
    Citation: Molecular Cancer 2023 22:71
  25. Immunotherapy has emerged to play a rapidly expanding role in the treatment of cancers. Currently, many clinical trials of therapeutic agents are on ongoing with majority of immune checkpoint inhibitors (ICIs)...

    Authors: Yong-Qiang Ao, Jian Gao, Shuai Wang, Jia-Hao Jiang, Jie Deng, Hai-Kun Wang, Bei Xu and Jian-Yong Ding
    Citation: Molecular Cancer 2023 22:70
  26. Extranodal natural killer/T-cell lymphoma (NKTL) is an aggressive type of non-Hodgkin lymphoma with dismal outcome. A better understanding of disease biology and key oncogenic process is necessary for the deve...

    Authors: Jianbiao Zhou, Sabrina Hui-Min Toh, Tze King Tan, Kalpnaa Balan, Jing Quan Lim, Tuan Zea Tan, Sinan Xiong, Yunlu Jia, Siok-Bian Ng, Yanfen Peng, Anand D. Jeyasekharan, Shuangyi Fan, Soon Thye Lim, Chin-Ann Johnny Ong, Choon Kiat Ong, Takaomi Sanda…
    Citation: Molecular Cancer 2023 22:69
  27. The development of head and neck squamous cell carcinoma (HNSCC) is a multi-step process, and its survival depends on a complex tumor ecosystem, which not only promotes tumor growth but also helps to protect t...

    Authors: Yingying Gong, Lisha Bao, Tong Xu, Xiaofen Yi, Jinming Chen, Shanshan Wang, Zongfu Pan, Ping Huang and Minghua Ge
    Citation: Molecular Cancer 2023 22:68
  28. Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in o...

    Authors: Zoufang Huang, Vivek P. Chavda, Rajashri Bezbaruah, Hemant Dhamne, Dong-Hua Yang and Hong-Bing Zhao
    Citation: Molecular Cancer 2023 22:67
  29. Due to the lack of effective treatment, metastasis is the main cause of cancer related deaths. TGF-β pathway has been reported related to cervical cancer metastasis. However, mechanism is still unclear.

    Authors: Guanglei Zhong, Qian Zhao, Zhiliao Chen and Tingting Yao
    Citation: Molecular Cancer 2023 22:66
  30. HOX transcript antisense intergenic RNA (HOTAIR) is an oncogenic non-coding RNA whose expression is strongly correlated with the tumor grade and prognosis of a variety of carcinomas including breast cancer (BC...

    Authors: Ganji Seeta Rama Raju, Eluri Pavitra, Sai Samyuktha Bandaru, Ganji Lakshmi Varaprasad, Ganji Purnachandra Nagaraju, Rama Rao Malla, Yun Suk Huh and Young-Kyu Han
    Citation: Molecular Cancer 2023 22:65
  31. Diffuse large B-cell lymphoma (DLBCL) exhibits significant genetic heterogeneity which contributes to drug resistance, necessitating development of novel therapeutic approaches. Pharmacological inhibitors of c...

    Authors: Elana Thieme, Nur Bruss, Duanchen Sun, Edward C. Dominguez, Daniel Coleman, Tingting Liu, Carly Roleder, Melissa Martinez, Krystine Garcia-Mansfield, Brian Ball, Patrick Pirrotte, Lili Wang, Zheng Xia and Alexey V. Danilov
    Citation: Molecular Cancer 2023 22:64
  32. Although metastasis is the foremost cause of cancer-related death, a specialized mechanism that reprograms anchorage dependency of solid tumor cells into circulating tumor cells (CTCs) during metastatic dissem...

    Authors: Hyunbin D. Huh, Yujin Sub, Jongwook Oh, Ye Eun Kim, Ju Young Lee, Hwa-Ryeon Kim, Soyeon Lee, Hannah Lee, Sehyung Pak, Sebastian E. Amos, Danielle Vahala, Jae Hyung Park, Ji Eun Shin, So Yeon Park, Han Sang Kim, Young Hoon Roh…
    Citation: Molecular Cancer 2023 22:63

    The Correction to this article has been published in Molecular Cancer 2023 22:135

  33. Molecularly targeted cancer therapies substantially improve patient outcomes, although the durability of their effectiveness can be limited. Resistance to these therapies is often related to adaptive changes i...

    Authors: Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, Hussein Kansou, Sahil Arora, Raj Kumar and Navnath S. Gavande
    Citation: Molecular Cancer 2023 22:62
  34. Kidney, bladder, and prostate cancer are the three major tumor types of the urologic system that seriously threaten human health. Circular RNAs (CircRNAs), special non-coding RNAs with a stabile structure and ...

    Authors: Zi-hao Zhang, Yue Wang, Ya Zhang, Sheng-Feng Zheng, Tao Feng, Xi Tian, Mierxiati Abudurexiti, Zhen-Da Wang, Wen-Kai Zhu, Jia-Qi Su, Hai-Liang Zhang, Guo-Hai Shi, Zi-Liang Wang, Da-Long Cao and Ding-Wei Ye
    Citation: Molecular Cancer 2023 22:61

    The Correction to this article has been published in Molecular Cancer 2023 22:73

  35. Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving tumorigenesis. Therefore, many studies have targ...

    Authors: Ruiwen Ruan, Li Li, Xuan Li, Chunye Huang, Zhanmin Zhang, Hongguang Zhong, Shaocheng Zeng, Qianqian Shi, Yang Xia, Qinru Zeng, Qin Wen, Jingyi Chen, Xiaofeng Dai, Jianping Xiong, Xiaojun Xiang, Wan Lei…
    Citation: Molecular Cancer 2023 22:60
  36. Recent studies suggest that cuproptosis, a novel mode of cell death, may be associated with the development of cancer. However, no studies are showing its role in tumorigenesis, progression, and prognosis. In ...

    Authors: Yan Qin, Yanling Liu, Xiaoyun Xiang, Xingqing Long, Zuyuan Chen, Xiaoliang Huang, Jianrong Yang and Wei Li
    Citation: Molecular Cancer 2023 22:59
  37. In recent years, tumor immunotherapy has made significant progress. However, tumor immunotherapy, particularly immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), benefits only a tiny proportion of pat...

    Authors: Hao Zhang, Lin Liu, Jinbo Liu, Pengyuan Dang, Shengyun Hu, Weitang Yuan, Zhenqiang Sun, Yang Liu and Chengzeng Wang
    Citation: Molecular Cancer 2023 22:58
  38. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-017-0615-x.

    Authors: Zhuo-yuan Lin, Guo Chen, Yan-qiong Zhang, Hui-chan He, Yu-xiang Liang, Jian-heng Ye, Ying-ke Liang, Ru-jun Mo, Jian-ming Lu, Yang-jia Zhuo, Yu Zheng, Fu-neng Jiang, Zhao-dong Han, Shu-lin Wu, Wei-de Zhong and Chin-Lee Wu
    Citation: Molecular Cancer 2023 22:56
  39. Circular RNAs (circRNAs) can be encapsulated into exosomes to participate in intercellular communication, affecting the malignant progression of a variety of tumors. Dysfunction of CD8 + T cells is the main fa...

    Authors: Zongqiang Hu, Gang Chen, Yingpeng Zhao, Hongqiang Gao, Laibang Li, Yanfeng Yin, Jie Jiang, Li Wang, Yuanyi Mang, Yang Gao, Shengning Zhang, Jianghua Ran and Li Li
    Citation: Molecular Cancer 2023 22:55
  40. Endometrial cancer (EC) is one of the most common gynecologic cancers and its incidence is rising globally. Although advanced EC has a poor prognosis; diagnosing EC at an earlier stage could improve long-term ...

    Authors: Yufei Shen, Wenqing Yang, Jiachen Liu and Yu Zhang
    Citation: Molecular Cancer 2023 22:53

    The Correction to this article has been published in Molecular Cancer 2023 22:76

  41. Inflammation is undoubtedly a hallmark of cancer development. Its maintenance within tumors and the consequences on disease aggressiveness are insufficiently understood.

    Authors: Abdel Jelil Njouendou, Tibor Szarvas, Arnol Auvaker Zebaze Tiofack, Rovaldo Nguims Kenfack, Pamela Derliche Tonouo, Sidonie Noa Ananga, Esther H. M. Dina Bell, Gustave Simo, Jörg D. Hoheisel, Jens T. Siveke and Smiths S. Lueong
    Citation: Molecular Cancer 2023 22:52
  42. Authors: Yongyan Wu, Yuliang Zhang, Xiwang Zheng, Fengsheng Dai, Yan Lu, Li Dai, Min Niu, Huina Guo, Wenqi Li, Xuting Xue, Yunfeng Bo, Yujia Guo, Jiangbo Qin, Yixiao Qin, Hongliang Liu, Yu Zhang…
    Citation: Molecular Cancer 2023 22:51

    The original article was published in Molecular Cancer 2020 19:99

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2022 Speed
    7 days submission to first editorial decision for all manuscripts (Median)
    76 days submission to accept (Median)

    2022 Usage 
    3,062,329 downloads
    4,920 Altmetric mentions